Video

Sacral neuromodulation shows efficacy in OAB patients with Parkinson’s disease

Author(s):

Urology Times staff

“Of those patients that did the test phase 82% of them actually went on to full implants,” says Sarah Martin, DO.

In this video, Sarah Martin, DO, discusses the background and key findings from the recent Neurourology & Urodynamics study, “Is sacral neuromodulation effective in patients with Parkinson's disease? A retrospective review,” for which she served as first author. Martin is an FPMRS fellow at Glickman Urological & Kidney Institute at Cleveland Clinic.

Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Modern medical office interior with computer and examination table | Image Credit: © New Africa - stock.adobe.com
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
Jeffrey A. Albaugh, PhD, APRN, CUCNS, answers a question during a Zoom video interview
Amy M. Pearlman, MD, interviews Gia Ching on Zoom
Related Content
Sunobinop shows promise in phase 1b trial for overactive bladder
January 7th 2025

Sunobinop shows promise in phase 1b trial for overactive bladder

Hannah Clarke
Sunobinop resulted in a reduction in urinary urgency, urinary frequency, and incontinence episodes over the treatment period compared with placebo.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
FDA approves vibegron for OAB symptoms in pharmacologically treated BPH
December 23rd 2024

FDA approves vibegron for OAB symptoms in pharmacologically treated BPH

Hannah Clarke
The approval of vibegron is supported by data from the phase 3 COURAGE trial.
Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff
“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
FDA greenlights pivotal trial of wearable bioelectronic device for OAB
December 12th 2024

FDA greenlights pivotal trial of wearable bioelectronic device for OAB

Hannah Clarke
The primary aims for the EVANESCE-II trial are to confirm the safety of the FemPulse System and to establish noninferiority to first-line tolterodine.
iTNM may provide comparable safety, efficacy to SNM for OAB, UUI
November 4th 2024

iTNM may provide comparable safety, efficacy to SNM for OAB, UUI

Hannah Clarke
The UUI responder rate was 71.8% among those who received SNM and 71.3% among those who received iTNM.
© 2025 MJH Life Sciences

All rights reserved.